Ekso Bionics® Announces Expanded Partnership with Kindred Healthcare for Multi-Unit EksoNR Order
May 11 2021 - 8:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced an expanded partnership with
Kindred Healthcare, LLC ("Kindred") bringing EksoNR, the most
clinically used robotic exoskeleton, to four of Kindred’s Long-Term
Acute Care (“LTAC”) Hospitals in the U.S. The multi-unit order
follows a successful pilot program of the EksoNR last year.
EksoNR has become a standard of care within
Kindred’s Inpatient Rehabilitation Hospitals by driving patient
outcomes in neurorehabilitation through early mobility and gait
training. In 2019, Kindred executed a proof of concept in the
Houston LTAC market and, after a successful implementation,
launched three additional Ekso programs in the Houston-metro area
in 2020. Kindred’s recent addition of acute inpatient
rehabilitation units (“ARUs”) to select LTAC hospitals across the
country offers a unique continuum of care designed to help patients
recover from debilitating effects of an acute injury, impairment,
or illness such as stroke, brain injury, spinal cord injury,
orthopedic injury, neurological conditions, amputation and trauma.
The LTAC locations incorporating EksoNR technology will be at
Kindred’s Florida hospitals in Green Cove Springs, Tampa/St. Pete,
Fort Lauderdale, and Melbourne.
“We are excited to expand our partnership with
Ekso Bionics and build on our leadership position in acute patient
services with the addition of these innovative EksoNR devices,”
said Mike Warrington, President of Kindred Healthcare’s Hospital
Division. “The EksoNR, combined with its specialized gait training,
has proven to deliver game changing results in helping patients
relearn how to walk following a devastating stroke, brain injury,
or spinal cord injury. Bringing the latest cutting edge exoskeleton
technology to our LTAC hospitals reinforces our commitment to
patient care.”
EksoNR is a robotic exoskeleton device that
empowers patients recovering from acquired brain injury, stroke,
and spinal cord injury to learn to walk again with a more natural
gait. The device contains posture and clinician control,
SmartAssist software, adaptive gait training, and pre-ambulatory
tools among other features designed for patients to mobilize
earlier and restore independence.
“Our robust partnership and this multi-unit
order with Kindred are a testament to our shared goals and
patient-driven values,” said Jack Peurach, CEO and President of
Ekso Bionics. “As the first network to explore the benefits of
EksoNR in the LTAC setting, Kindred has always been at the
forefront of patient care. We look forward to continue advancing
our relationship throughout the Kindred network."
To find a location with EksoNR near you, visit
eksobionics.com/centers.
About Kindred HealthcareKindred
Healthcare, LLC is the nation’s leading specialty hospital company
delivering acute health services in its long-term acute care
hospitals, inpatient rehabilitation hospitals, acute rehabilitation
units, and behavioral health line of business, all specializing in
treating the most medically complex patients. Based in Louisville,
Kentucky, and ranked as one of Fortune magazine’s Most Admired
Healthcare Companies for nine years, Kindred’s mission is to help
our patients reach their highest potential for health and healing
with intensive medical and rehabilitative care through a
compassionate patient experience. For more information, go
to www.kindredhealthcare.com. You can also follow us
on Facebook, LinkedIn, and Twitter.
About Ekso Bionics®Ekso
Bionics® is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance, and mobility across medical and industrial applications.
Founded in 2005, Ekso Bionics continues to build upon its
industry-leading expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe. Ekso Bionics is
headquartered in the San Francisco Bay Area and is listed on the
Nasdaq Capital Market under the symbol “EKSO.” For more
information, visit: www.eksobionics.com or follow @EksoBionics on
Twitter.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding the potential benefits, performance and
effectiveness of the Company’s products and systems, including
EksoNR, statements by Mr. Warrington and Mr. Peurach regarding the
expansion and advancement of the relationship between the Company
and Kindred, and the assumptions underlying such statements. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances and may not be
realized because they are based upon the Company’s current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the ongoing COVID-19 pandemic and its
impact on the Company’s financial condition and business, the
highly competitive markets in which the Company’s products are
sold, the Company's significant losses to date and anticipated
future losses, the new and unproven nature of the market for the
Company’s products, the long and variable sales cycles for the
Company’s products, the factors outside the Company’s control that
affect the international sales of its products, the costs related
to and impacts of potential failure of the Company to obtain or
maintain protection for the Company's intellectual property rights,
the failure of the Company to obtain or maintain regulatory
approval to market the Company's medical devices, and risks related
to product liability, recall and warranty claims. These and other
factors are identified and described in more detail in the
Company’s filings with the U.S. Securities and Exchange Commission.
To learn more about Ekso Bionics please visit the Company’s website
at www.eksobionics.com or follow @EksoBionics on Twitter. The
Company does not undertake to update these forward-looking
statements.
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Sep 2023 to Sep 2024